{{Short description|Monoclonal antibody}} {{Infobox drug | type = mab | image = | alt = | mab_type = <!-- mab, Fab, F(ab')2, Fab', scFv, di-scFv, 3funct, clFab, BiTE --> | source = <!-- a, e, i, o, u, xi/a, zu/a, xizu/a, axo, ... --> | target = <!-- antigen, not the code number of the monoclonal antibody! --> <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A/B1/B2/B3/C/D/X --> | pregnancy_US = <!-- A/B/C/D/X --> | pregnancy_category= | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F--> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> | legal_NZ = <!--Class A, B, C --> | legal_status = Investigational | routes_of_administration = <!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = <!-- Identifiers --> | CAS_number = 1884474-47-8 | ATC_prefix = <!-- 'none' when not assigned --> | ATC_suffix = | PubChem = | DrugBank = | synonyms = Anti-LINGO-1 }}

'''BIIB033''' (also known as Anti-LINGO-1) is a monoclonal antibody targeting LINGO1. As of 2015 it was being developed by Biogen as a treatment for diseases such as multiple sclerosis and optic neuritis.<ref>{{Cite web|title = Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test|url = https://www.forbes.com/sites/matthewherper/2015/04/14/biogen-ms-drug-results-are-mildly-encouraging-in-eye-disease-test/|website = Forbes|access-date = 2015-10-13}}</ref><ref>{{ClinicalTrialsGov|NCT01864148|Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex}}</ref><ref>{{cite journal | vauthors = Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L, Zhao J, Parr E, Cadavid D | display-authors = 6 | title = Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033 | journal = Neurology | volume = 1 | issue = 2 | article-number = e18 | date = August 2014 | pmid = 25340070 | pmc = 4202679 | doi = 10.1212/NXI.0000000000000018 }}</ref>

== See also == * Ocrelizumab

== References == {{Reflist}}

{{Monoclonals for immune system}}

Category:Monoclonal antibodies Category:Experimental drugs

{{monoclonal-antibody-stub}}